Details for Patent: 6,248,775
✉ Email this page to a colleague
Title: | .alpha.- and .beta.-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
Abstract: | .alpha.- and .beta.-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. |
Inventor(s): | Vazquez; Michael L. (Gurnee, IL), Mueller; Richard A. (Glencoe, IL), Talley; John J. (Brentwood, MO), Getman; Daniel P. (Chestertfield, MO), DeCrescenzo; Gary A. (St. Peters, MO), Freskos; John N. (Clayton, MO), Bertenshaw; Deborah E. (Brentwood, MO), Heintz; Robert M. (Ballwin, MO) |
Assignee: | G. D. Searle & Co. (Chicago, IL) |
Filing Date: | Apr 08, 1999 |
Application Number: | 09/288,080 |
Claims: | 1. A compound represented by the formula: ##STR827## or a pharmaceutically acceptable salt, prodrug, or ester thereof, wherein P.sup.1 represents alkoxycarbonyl, aralkoxycarbonyl, alkylcarbonyl, cycloalkylcarbonyl, cycloalkylalkoxycarbonyl, cycloalkylalkanoyl, alkanoyl, aralkanoyl, aroyl, aryloxycarbonyl, aryloxycarbonylalkyl, aryloxyalkanoyl, heterocyclylcarbonyl, heterocyclyloxycarbonyl, heterocyclylalkanoyl, heterocyclylalkoxycarbonyl, heteroaralkanoyl, heteroaralkoxycarbonyl, heteroaryloxycarbonyl, heteroaroyl, alkyl, alkenyl, cycloalkyl, aryl, aralkyl, aryloxyalkyl, heteroaryloxyalkyl, hydroxyalkyl, aminocarbonyl, aminoalkanoyl, and mono- and disubstituted aminocarbonyl and mono- and disubstituted aminoalkanoyl radical wherein the substituents are selected from the group consisting of alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkyalkyl radicals; or where said aminoalkanoyl radicals is disubstituted, said substituents along with the nitrogen atom to which they are attached form a heterocycloalkyl or heteroaryl radical; P.sup.2 is hydrogen; R.sup.2 is an alkyl, aryl, cycloalkyl, cycloalkylalkyl or aralkyl radical, which radicals are optionally substituted with a group selected from alkyl and halogen radicals, nitro, cyano, CF.sub.3, --OR.sup.9, --SR.sup.9, wherein R.sup.9 is a hydrogen, alkyl or halogen radical; R.sup.3 is a hydrogen, alkyl, haloalkyl alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heteroaryl, heterocycloalkylalkyl, aryl, aralkyl, heteroaralkyl, aminoalkyl or mono- or disubstituted aminoalkyl radical, wherein said substituents are selected from the group consisting of alkyl, aryl, arakyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, and heterocycloalkylalkyl radicals, or where the aminoalkyl radical is disubstituted, said substituents along with the nitrogen atom to which they are attached, form a heterocycloalkyl or a heteroaryl radical; and R.sup.4 is a radical as defined by R.sup.3 except for hydrogen. 2. A compound of claim 1 wherein P.sup.1 is heteroclyloxycarbonyl. 3. A compound of claim 2 wherein the heterocycloxycarbonyl is selected from the following: ##STR828## 4. A compound of claim 3 which is: ##STR829## 5. A compound of claim 3 which is: ##STR830## 6. A compound of claim 3 which is: ##STR831## 7. A compound of claim 3 which is: ##STR832## 8. A compound of claim 3 which is: ##STR833## 9. A compound of claim 3 which is: ##STR834## 10. A compound of claim 3 which is: ##STR835## 11. A compound of claim 3 which is: ##STR836## 12. Method of treating a retroviral infection comprising administering an effective amount of a compound of claim 2. 13. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier. 14. Method of inhibiting a retrovirus protease comprising administering a protease inhibiting amount of a composition of claim 13. 15. Method of claim 14 wherein the retrovirals protease is HIV protease. 16. Method of treating a retrovirus infection comprising administering an effective amount of a composition of claim 13. 17. Method of claim 16 wherein the retrovirals infection is an HIV infection. 18. Method for treating AIDS comprising administering an effective amount of a composition of claim 13. |